| Old Articles: <Older 42661-42670 Newer> |
|---|
 |
The Motley Fool
July 30, 2010
Brian Orelli |
3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company.   |
The Motley Fool
July 30, 2010
Dave Mock |
A Big Upgrade for Guess? Bullish calls on this clothing and fashion firm comes from more than just one analyst. |
The Motley Fool
July 30, 2010
Morgan Housel |
How Much Further Do Home Prices Need to Fall? These numbers tell me we're not out of the woods just yet. |
The Motley Fool
July 30, 2010
Christopher Barker |
Let the Golden Bonanza Begin Goldcorp and others deliver the goods with expanding margins. |
The Motley Fool
July 30, 2010
Alyce Lomax |
Green Mountain Rolls in the Green Can the coffee company keep on perking along? |
The Motley Fool
July 30, 2010
Toby Shute |
This Company Will Win the Shale Race During the deepwater pause, NOV's shale strength comes to the fore. |
The Motley Fool
July 30, 2010
Anders Bylund |
More Upside: Cypress or Synaptics? Synaptics was supposed to win the touchscreen wars, but it's off to a slow start. |
The Motley Fool
July 30, 2010
Brian Orelli |
MannKind: Strengths, Weaknesses, Opportunities, Threats It's all about the inhaled insulin. |
The Motley Fool
July 30, 2010
Anders Bylund |
The Future Is Bright for MEMC Change is hard for Mr. Market, and he doesn't understand what's happening to semiconductor wafer maker MEMC. You should take advantage of this ignorance. |
The Motley Fool
July 30, 2010
Cliff D'Arcy |
Which Is the Better Big Pharma? AstraZeneca is having a good 2010 -- and its shares are enjoying a great run, too. Here's how it compares to GlaxoSmithKline. |
| <Older 42661-42670 Newer> Return to current articles. |
